Germany's Curetis Adds $6.4M to Series A Financing to Prep MDx System for US Trials
May 19, 2011
Germany's Curetis Adds $6.4M to Series A Financing to Prep MDx System for US Trials
The trials, expected to begin in the second half of this year, will be for its benchtop automated DNA-testing platform and its first cartridge-based test for multiple causative agents of pneumonia and antibiotic-resistance markers.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Germany's Curetis Begins Clinical Trial for MDx Platform, Pneumonia Test Cartridge
March 1, 2012 / PCR Insider - German MDx Startup Curetis Nets Roche Venture Fund, Forbion as New Investors
October 27, 2011 / PCR Insider - Dx Focus: IdahoTech FilmArray; Curetis Unyvero Pneumonia Assay; IMDx GBS Test; Lab21's US CLIA Lab
May 17, 2012 / PCR Insider - Dx Focus: PEPFAR Funding Drives Cepheid TB Test Uptake; Curetis Starts US Trials for MDx System
December 6, 2012 / PCR Insider - Curetis, Heraeus Medical Partner to Develop MDx Test for Implant, Tissue Infections
September 20, 2012 / PCR Insider